Moderna

Wacker Chemie has opened a new Biotechnology Center in Munich with space for 90 employees and state-of-the-art equipment to concentrate and intensify biotech research activities.

Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to advance the industrialization of Sensible's first-in-class cell-based mRNA manufacturing platform.

Applied DNA Sciences implemented a 27% workforce reduction and ceased operations at Applied DNA Clinical Labs to focus exclusively on its synthetic DNA manufacturing subsidiary LineaRx.

Laverock Therapeutics has expanded its seed funding round to more than £20 million, with the latest £6.5 million extension led by Calculus Capital and including participation from Eli Lilly and Company.

The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.

Cambridge Healthcare Innovations has announced Quattrii, a dry powder inhaler engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation with at least 70% lung delivery efficiency.

Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.

Fareva has launched a new GMP sterile pilot unit at its Pau site in France, designed to produce liquid and lyophilized injectable forms for biotechnology-derived medicines.

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.

DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.